Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

 Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

Shots:

  • NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs
  • The focus of the agreement is to develop novel immunotherapies using NextCure’s FIND-IO technology in the fields of oncology
  • FIND-IO platform has ability to identify cell surface molecular interactions while converting them into disease modifying immunotherapies

Click here to read full press release/ article | Ref: Eli Lilly | Image: Biospace

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post